By Kamal Choudhury Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a multi-year partnership worth more ...

Read more about Artificial intelligence could change future of antimicrobial drug discovery: Here's why on Devdiscourse ...

AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda ...

As China's new drug R&D enters the 'deep waters' of homogeneous competition, the path for followers has become increasingly ...

Iambic’s AI-platform includes Enchant, a multimodal transformer model designed to predict both preclinical and clinical endpoints, alongside NeuralPLexer. 1 Enchant recently received Nvidia HGX B200 ...

Explore AI in drug discovery and its journey from promise to proof in 2025 with significant achievements and challenges faced.

In an interview with Technology Networks, Dr. Daniel Reker discusses how machine learning is improving data-scarce areas of ...

For patients taking medications that don't work as expected or pharmaceutical companies struggling with clinical trial ...

Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...

SPT Labtech, which designs and develops automated instrumentation and consumables for life sciences, and BellBrook Labs - a ...

Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs through a multi-year tech and ...

Digital twins revolutionize drug discovery by integrating AI and biological data, enhancing prediction, trial design, and decision-making in precision medicine.